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Abstract
Background: Tuberculosis Trials Consortium Study 28, was a double blind, randomized, placebo-controlled, phase 2 clinical
trial examining smear positive pulmonary Mycobacterium tuberculosis. Over the course of intensive phase therapy, patients
from African sites had substantially delayed and lower rates of culture conversion to negative in liquid media compared to
non-African patients. We explored potential explanations of this finding.
Methods: In TBTC Study 28, protocol-correct patients (n=328) provided spot sputum specimens for M. tuberculosis culture
in liquid media, at baseline and weeks 2, 4, 6 and 8 of study therapy. We compared sputum culture conversion for African
and non-African patients stratified by four baseline measures of disease severity: AFB smear quantification, extent of disease
on chest radiograph, cavity size and the number of days to detection of M. tuberculosis in liquid media using the Kaplan-
Meier product-limit method. We evaluated specimen processing and culture procedures used at 29 study laboratories
serving 27 sites.
Results: African TB patients had more extensive disease at enrollment than non-African patients. However, African patients
with the least disease by the 4 measures of disease severity had conversion rates on liquid media that were substantially
lower than conversion rates in non-African patients with the greatest extent of disease. HIV infection, smoking and diabetes
did not explain delayed conversion in Africa. Some inter-site variation in laboratory processing and culture procedures
within accepted practice for clinical diagnostic laboratories was found.
Conclusions: Compared with patients from non-African sites, African patients being treated for TB had delayed sputum
culture conversion and lower sputum conversion rates in liquid media that were not explained by baseline severity of
disease, HIV status, age, smoking, diabetes or race. Further investigation is warranted into whether modest variation in
laboratory processes substantially influences the efficacy outcomes of phase 2 TB treatment trials or if other factors (e.g.,
nutrition, host response) are involved.
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Introduction
Two month culture conversion has been used as a measure of
efficacy in the assessment of drugs used to treat TB in phase 2 trials
[1]. The timing of culture conversion is influenced by bacillary
quantitation on smear and extent of disease on chest radiograph
(CXR), particularly cavitation [2,3]. More recently, lower rates of
culture conversion have been associated with diabetes [3,4,5], lack
of directly observed therapy [6], HIV infection [6] and smoking
[7,8].
The TB Trials Consortium (TBTC) recently completed a
double-blind, randomized, placebo-controlled, phase 2 trial
examining the substitution of moxifloxacin for isoniazid (INH)
during the first 2 months (intensive phase) of therapy of drug-
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The study was conducted at urban sites in Brazil, Canada,
South Africa, Spain, Uganda and the United States. In this
study, the proportion of patients with negative cultures at 8
weeks of therapy did not differ significantly between patients in
the INH and moxifloxacin arms [9]. In multivariate analysis,
positive sputum culture at 8-weeks was associated with
enrollment in Africa, cavitation on baseline CXR, higher
bacillary load on baseline smear and increasing age, but not
HIV co-infection.
A difference in the rate of culture conversion between patients
at African and non-African sites was also observed in TBTC Study
27, a phase 2 clinical trial in which moxifloxacin was substituted
for ethambutol during the first 2 months of therapy of drug-
susceptible smear positive TB [10].
In both TBTC Studies 27 and 28, the definition of sputum
culture conversion was based upon the combined results of both
liquid and solid media such that a positive result on either media
type was considered positive. Since liquid media are more sensitive
than solid media in detecting the growth of M. tuberculosis, culture
status in Studies 27 and 28 was most influenced by the liquid
media results.
We explored potential contributions of the following factors to
explain lower culture conversion rates in Africa: 1) baseline
severity of disease, 2) microbiological procedures, and 3)
pharmacokinetic characteristics (published elsewhere, [11]).
Methods
Epidemiologic Investigation
This analysis included 328 protocol-correct participants in
Study 28 [9]. Patients provided spot sputum specimens for AFB
smear microscopy and culture, on both solid and liquid media, at
baseline and weeks 2, 4, 6, and 8 of study therapy [9]. Thereafter
spot sputa were obtained monthly until 2 consecutive specimens
were culture-negative. Mycobacterial isolates from protocol-
correct participants were confirmed to be M. tuberculosis complex
and susceptible to isoniazid, fluoroquinolones, rifampin, and
pyrazinamide. We defined culture conversion as the first negative
sputum culture with at least one subsequent negative culture and
no subsequent positive results.
We examined the probability of sputum culture conversion in
liquid media using smoothed Kaplan-Meier plots, calculated at
days 15, 29, 43, 57 after the start of therapy corresponding to
weeks 2, 4, 6, 8, respectively. We investigated four stratified
measures of disease extent at enrollment for African v. non-
African patients. These stratified measures included: 1) Smear
status normalized to the WHO standard (0–1+,2 +,3 +), 2)
Radiographic extent of pulmonary involvement (,25%, 25%–
50%, .50%) on baseline CXR, 3) aggregate cavity size on CXR
(absent, ,4c m ,$4 cm), and 4) the number of days-to-detection
( D T D )o fg r o w t hi nl i q u i dm e d i af o rM. tuberculosis positive
specimens (0–5 days, 6–9 days, 10+ days). The Wilcoxon test for
paired samples was used to determine whether culture
conversion curves were significantly different between African
and non-African patients with equivalent measures of disease
severity[12].
Information about smoking, diabetes, and self-designated race
was obtained from participants through interview by study staff.
HIV testing was performed on all study participants.
This work is a secondary analysis of data from TBTC Study 28
which was registered on ClinicalTrails.gov with the identifier
NCT00144417. The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1. The protocol for TBTC Study
28 was approved by the CDC Human Research Protection Office
and the 50 institutional review boards of the 27 sites enrolling
patients. Patients enrolled in TBTC Study 28 provided written
informed consent to participate in the study.
Laboratory Methods and Investigation
Each enrolling site submitted sputum specimens to a local
microbiology laboratory that participates in a quality assurance
testing program for both smear and culture. Twenty-nine
laboratories processed and cultured sputum for M. tuberculosis
from TBTC Study 28 patients. Sputum smears were prepared
from concentrated, decontaminated specimens and read using
either the ATS/CDC[13] or WHO[14] smear grading systems
and then harmonized to the WHO grading system for analysis.
We reviewed laboratory practices and processes at these
laboratories including media type used, decontamination proce-
dures and inoculation volume. All laboratories used N-acetyl-L-
cysteine (NALC)/sodium hydroxide (NaOH) for specimen decon-
tamination.
The TBTC site in Uganda enrolled 55% of protocol-correct
Study 28 patients of which many had delayed culture conversion
so further investigation of the M. tuberculosis isolates from Uganda
was undertaken. As a routine practice at this laboratory, all
positive liquid culture tubes were subcultured on blood agar plates
and stained using the Ziehl-Neelson method. Nucleic acid
amplification of IS6110 was performed routinely on all AFB-
positive culture tubes at enrollment to assess for M. tuberculosis
complex. To assess for cross-contamination in the Ugandan
laboratory and for potential re-infection with a different strain of
M. tuberculosis a convenience sample of 21 pairs of baseline and 8-
week isolates from Ugandan patients underwent spoligotyp-
ing[15,16], MIRU[17] and/or RFLP[18] analysis at CDC.
Results
Of the 328 protocol-correct patients in TBTC Study 28, 213
(65%) were enrolled in Africa, including 182 (55%) from Uganda
and 31 (9%) from South Africa. Among the remainder, 19 (6%)
were enrolled in Brazil, 12 (4%) in Spain, and 84 (26%) in North
America.
After 8 weeks of study therapy, sputa cultured in liquid media
from African site patients were 29% less likely to have converted to
negative than non-African patients (p,0.001; Wilcoxon test
comparing the curves). Based on cultures on solid media, African
site patients were 10% more likely to have converted than from
non-African patients (p=0.6; Wilcoxon test comparing the curves)
(Figure 1). In Africa there was a 45% difference in the rate of
conversion between solid and liquid media while there was only a
9% difference in non-African patients.
Baseline Extent of Disease
At baseline African patients had a higher bacillary load based
on sputum smear and a smaller number of days required for
detection of M. tuberculosis growth in liquid media, compared to
non-African patients (Table 1). Compared to non-African patients,
a higher proportion of African patients had cavitary disease, and
African patients had larger cavities and more lung fields involved
by tuberculous lesions.
To evaluate whether more severe disease in African patients
explained the lower culture conversion rates in liquid media in
African patients, we evaluated the probability of culture
conversion by week of therapy for African and non-African
patients stratified by severity of disease for baseline smear status
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(Figure 4) and the number of days to detect growth in liquid media
(Figure 5).
Within each region (i.e., African, non-Africa) for each of these
measures of extent of disease at enrollment, the relationship
between severity and time to conversion was consistent and
generally as expected. Patients with the most severe measures of
disease had slower sputum culture conversion in liquid media
compared to patients with moderate disease, who had slower
conversion than patients with the least severe measures of
disease.
However, for all four baseline measures of disease examined,
when compared at equivalent levels of severity, African patients
had substantially lower conversion rates in liquid media than non-
African patients. In fact, African patients with the least severe
measures of disease consistently had conversion rates similar to or
lower than non-African patients with the most severe measure of
disease. The curves for all 12 comparisons of the time to sputum
culture conversion for equivalent measures of disease severity
shown in figures 2, 3, 4, 5 were significantly different between
African and non-African patients (See Table 2).
Compared with patients from non-African sites, those from
African sites had lower prevalences of smoking (63% versus 27%,
p.0.001) and of prior diagnosis of diabetes mellitus (17% versus
0%, p.0.001). African patients were significantly younger than
non-African patients (29.4 years vs. 40.5 years, p,0.001). Of the
35 HIV-infected, protocol-correct patients, 32 were from African
sites. Among African patients, HIV-positive patients had slightly
higher conversion rates in liquid media compared to HIV-negative
patients (Figure 6). Culture-conversion rates by race (black and
non-black) were examined to determine if non-African patients of
black race had lower conversion rates (Figure 7). At non-African
sites the time to conversion in liquid media did not differ
substantially between black (n=26) and non-black patients
(n=80), but both were significantly lower than that in African
patients (p,0.001, log-rank test). Therefore, smoking, diabetes,
age, HIV status, and race did not explain lower sputum culture
conversion rates in Africa.
Figure 1. Probability of sputum culture conversion among TBTC Study 28 protocol-correct patients, by week of treatment, region
(Africa vs. non-Africa) and culture media type (solid vs. liquid).
doi:10.1371/journal.pone.0018358.g001
Table 1. Baseline measures of severity of disease, TBTC Study
28 protocol-correct patients, Africa vs. non-Africa.
Smear Status* 0–1+ 2+ 3+
Africa (N=213) 24% 32% 44%
Non-Africa (N=105) 51% 29% 20%
Radiographic extent
of involvement
,25% 25%–50% .50%
Africa (N=213) 17% 50% 33%
Non-Africa (N=105) 34% 37% 29%
Cavitary size Absent ,4c m $4c m
Africa (N=213) 23% 29% 48%
Non-Africa (n=105) 32% 47% 21%
Days to Detection** 10+ 6–9 #5
Africa (N=212) 26% 27% 47%
Non-Africa (N=98) 41% 42% 17%
*using WHO criteria.
**in liquid media.
doi:10.1371/journal.pone.0018358.t001
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treatment, TBTC Study 28 protocol-correct patients.
doi:10.1371/journal.pone.0018358.g002
Figure 3. Probability of sputum culture conversion in liquid media by baseline aggregate cavity size, African/non-African site and
week of treatment, TBTC Study 28 protocol-correct patients.
doi:10.1371/journal.pone.0018358.g003
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African site and week of treatment, TBTC Study 28 protocol-correct patients.
doi:10.1371/journal.pone.0018358.g004
Figure 5. Probability of sputum culture conversion in liquid media by baseline number of days to detection (DTD) of growth in
liquid media, African/non-African site and week of treatment, TBTC Study 28 protocol-correct patients.
doi:10.1371/journal.pone.0018358.g005
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Among the 29 laboratories processing mycobacterial cultures
for TBTC Study 28: 1) the final concentration of NaOH used for
decontamination ranged from 1% to 3% (mean 1.6%, median
1.25%), Most of the non-African laboratories decontaminated with
a final NaOH concentration of 2% while the two African
laboratories processed specimens using a final NaOH concentra-
tion of 1% and 1.5%, 2) the median duration of decontamination
was 15 minutes (range 15–20 min), 3) inoculation volume was
0.5 ml for liquid media for all but one site (See Table 3).
To assess whether differences in the final concentration of
NaOH used in specimen decontamination might explain delayed
conversion among African patients we examined the probability of
culture conversion stratified by NaOH final concentration used in
decontamination and geographic region of enrollment. We found
that through week 6 of TB treatment non-African patients whose
sputum specimens were decontaminated with NaOH concentra-
tions ,2.0% (range 1.0% –1.5%) had almost identical times to
conversion as non-African patients with specimens decontaminat-
ed with NaOH concentrations $2.0% (range 2.0%–3.0%).
However, at week 8 it was surprising to find that non-African
patients whose sputum specimens were decontaminated with
NaOH concentrations ,2.0% had a higher rate of conversion
than non-African patients with specimens decontaminated with
NaOH concentrations $2.0% (Figure 8) suggesting that the
NaOH concentration does not explain the observed delayed
culture conversion for patients at African sites.
All isolates from Ugandan Study 28 protocol-correct patients
were confirmed at enrollment and week-8 to be M. tuberculosis
complex. All of the baseline and week 8 isolate pairs from 21
patients matched genotypically using RFLP, MIRU, and spoligo-
typing methods, suggesting that cross-contamination or re-
infection did not explain the low culture negative conversion rate
in liquid media among African patients.
Discussion
Interest in geographic differences in response to TB chemo-
therapy dates back to 1956 when Fox et al. compared clinical,
radiographic, and microbiologic outcomes in patients from Britain
and Uganda [19]. In TBTC study 28 during the first 8 weeks of
therapy we found later sputum culture conversion and lower rates
of conversion in liquid media in African patients compared to non-
African patients, despite African patients having comparatively
higher conversion rates on solid media. African patients had more
severe disease when their therapy was begun. However when we
evaluated conversion rates stratified by varying levels of disease
severity it became clear that our measures of baseline severity of
disease did not explain the lower and delayed culture conversion in
liquid media in African patients. In fact, African patients with the
lowest severity of disease had conversion rates in liquid media that
were similar to or lower than non-African patients with the highest
severity of disease.
Some studies suggest that smoking [7,8], diabetes [3,4,5],
increasing age [20] and HIV positive status [6] are associated with
delayed conversion. In Study 28, African patients had a lower
prevalence of smoking and diabetes and were younger compared
to non-African patients, so these conditions did not appear to
contribute to the lower conversion rates in Africa. Patients with
HIV infection actually had slightly higher conversion rates in
liquid media compared to HIV-negative patients.
In Study 28 the administration of all doses of anti-TB drugs
were directly observed. In an intensive pharmacokinetic sub-study
performed on a convenience sample of 72 patients enrolled in
TBTC Studies 27 and 28 (37 African and 35 non-African), the
mean AUC0-24 for rifampin and moxifloxacin did not differ
between African and non-African patients [11]. Isoniazid levels
were not examined. We did not find a pharmacokinetic reason for
lower conversion rates among Africans.
A panel of experienced mycobacteriologists, clinicians, and
epidemiologists reviewed laboratory processes in the context of the
site-specific conversion rates and the number of patients
represented. They determined that the laboratories were operating
within accepted guidelines for conducting mycobacterial cul-
tures[21]. We found some variation in laboratory processes (e.g.,
decontamination procedures) that might have led to differences in
the rates of culture conversion. In particular, the concentration of
NaOH used during specimen decontamination was generally
lower at African sites (albeit with longer time for decontamination).
Laboratory studies done on sputum seeded with bacteria and M.
tuberculosis H37Ra revealed that decontamination with NALC-
NaOH with final concentrations of 1–2% NaOH and decontam-
ination treatment times of up to 30 minutes did not affect the
viability of M. tuberculosis when grown on solid media [22].
However a study of patient sputum specimens collected prior to
initiation of TB therapy suggested that relatively small increases in
the final NaOH concentration used in decontamination from 1%
to 1.25% significantly decreased the recovery of M. tuberculosis on a
solid media [23]. When we evaluated the effect of the NaOH
concentration on liquid culture results after the initiation of TB
therapy, stratified by geographic region, we found that the NaOH
concentration did not explain delayed conversion in African
patients compared to those at non-African sites.
At baseline, prior to the initiation of therapy, solid and liquid
media performed equally well for isolating M. tuberculosis from the
sputa of the smear-positive patients enrolled in Study 28. As
therapy progressed, at both African and non-African sites, patients
had lower conversion rates in liquid media compared to solid
media. This is expected, as liquid media allow for growth of some
Table 2. Wilcoxon test P-values for the probability of sputum
culture conversion in liquid media comparing African and
non-African patients with equivalent baseline measures of
disease severity during the first eight weeks of tuberculosis
therapy as shown in figures 2, 3, 4, 5, TBTC Study 28.
p-value
Sputum Smear
low load (0, 1+) 0.001
moderate load (2+) 0.003
high load (3+) ,0.001
Radiographic Extent of Involvement
limited extent (,25%) 0.001
moderate extent (25–50%) ,0.001
extensive (.50%) 0.001
Aggregate Cavity Size
cavities absent ,0.001
cavities ,4 cm 0.001
cavities .4 cm 0.045
Number of Days to Detection in Liquid Media
10+ DTD 0.005
6–9 DTD ,0.001
0–5 DTD 0.010
doi:10.1371/journal.pone.0018358.t002
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TBTC Study 28 protocol-correct patients.
doi:10.1371/journal.pone.0018358.g006
Figure 7. Probability of sputum culture conversion in liquid media by race (black and non-black), African/non-African site and week
of treatment, TBTC Study 28 protocol-correct patients.
doi:10.1371/journal.pone.0018358.g007
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patients, TBTC Study 28.
Site
Number of
Protocol-correct
Patients Enrolled
Solid
Media
Type* Liquid Media Type
Final Sodium Hydroxide
Concentration used for
specimen Decontamination
Decontamination
Time (min)
Inoculation
volume (ml)
on liquid media
Uganda 182 7H10 MGIT (82%)
BACTEC 460 (18%)***
1.5% 20 0.50
South Africa 31 7H11 MGIT 1.0% 15 0.50
Brazil 19 LJ MGIT 2.0% 20 0.50
North Texas 13 LJ MGIT 2.0% 15 0.50
South Texas 12 LJ BACTEC 460 (75%)***
MGIT (25%)
2.0% 15 0.50
Spain 12 LJ MGIT (75%)
MB/BacT (25%)
2.0% 15 0.50
Houston 8 LJ MB/BacT 2.0% 15 0.50
Denver 7 7H11 MGIT 1.5% 15 0.50
New Jersey 7 7H11 MGIT 1.0% 20 0.50
Other non-
African sites**
37 LJ or 7H11 MGIT (73%)
BACTEC 460 (14%)***
MB/BacT (13%)
1.0% –3.0%
(median 1.0)
13–20
(median 15)
0.50–0.70 (median 0.50
*If multiple solid media were inoculated at a site laboratory for analysis we used only one solid media result based upon media type. Solid media results were used in
the following order of preference - LJ .7H11 .7H10.
**Represents 18 laboratories serving 15 study sites.
***Cultures in BACTEC 460 were read daily for the first 10 days and approximately weekly thereafter.
doi:10.1371/journal.pone.0018358.t003
Figure 8. Probability of sputum culture conversion in liquid media by NaOH final concentration used for specimen
decontamination, African/non-African site and week of treatment, TBTC Study 28 protocol-correct patients.
doi:10.1371/journal.pone.0018358.g008
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media[24]. Unexpectedly, the difference in conversion rates
between solid and liquid media was much greater in Africa. This
finding of large differences in the yield of solid and liquid media for
M. tuberculosis for African patients receiving therapy is not unique
to TBTC Study 28. A similar clinical trial conducted in South
Africa by the OFLOTUB group found that at 8 weeks of TB
therapy the proportion of sputum cultures that were negative on
solid media (7H11) was twice that found on liquid media
(MGIT)[25]. Joloba et. al. studied sputum culture conversion on
both solid (7H10 selective) and liquid media (BACTEC 460)
during the course of TB therapy for both HIV infected and
uninfected populations. They also found that conversion in liquid
media was lower and substantially delayed compared to that of
solid media for both populations[26].
Regional differences in outcomes of TB therapy are not unique
to TBTC studies. In a recent phase 3 trial conducted in Brazil, the
Philippines and Uganda examining treatment shortening for HIV
negative adults with non-cavitary TB and negative 2-month
sputum culture on solid media, patients from Uganda were more
likely to relapse than participants from Brazil or the Philip-
pines[27]. This study was stopped early because patients in the 4-
month treatment arm had significantly more relapse (13 relapses
among 196 patients) than those in the 6-month treatment arm (3
of 198). Among the 16 relapses, 12 (75%) occurred in the Ugandan
patients and 4 (25%) in Brazilian patients. Initial sputum smear
grade and the number of lung zones involved by tuberculous
lesions were greater among patients enrolled in Uganda. In the
multivariate analysis, enrollment at the Uganda site was an
independent risk factor for relapse after accounting for baseline
sputum smear and radiographic extent of disease. Two-month
sputum culture results in liquid media were not reported in that
study.
Recent TB trials illustrate important advantages and disadvan-
tages of different approaches to phase 2 clinical trials
[9,10,25,27,28]. Multicenter international studies are likely to
enroll more rapidly and to be more representative and easier to
generalize, they also allow examination for regional differences in
response to therapy. However, the potential influence that
variability in laboratory or other procedures might have on the
interpretation of clinical trial results must be considered. While
laboratories engaged in clinical trials should meet recognized
clinical diagnostic standards for culturing mycobacteria, the
degree of heterogeneity of procedures allowed to meet these
routine clinical diagnostic standards may not be sufficient for early
phase controlled clinical trials. Further research is needed to
determine whether and how modest differences in processing and
culturing of sputa influence microbiological outcomes over the
course of TB therapy in phase 2 studies. Such studies should focus
on determining the principle processes that contribute to
variability in microbiological outcomes measured during clinical
trials. Laboratory processes that diminish the sensitivity or
specificity of microbial biomarkers of treatment outcomes (e.g.,
8-week culture conversion) will influence the ability of both single
site and multi-site studies to determine the relative efficacy of drug
regimens. Efforts to optimize the performance characteristics of
microbiological tests in predicting treatment failure and relapse are
needed if we hope to make good decisions regarding which drugs
and regimens to move forward into phase 3 clinical trials. If, after
investigation, variations in laboratory practices are not found to
explain geographic difference in time to culture conversion, then
alternative explanations (e.g., differences in socioeconomic/
nutritional status, host immunity, or microbial pathogenesis)
should be explored.
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